text: Independent research conducted by Antibody Solutions and published or presented at scientific conferences include the following:
  * Generation of Neutralizing Human Monoclonal Antibodies Against a Therapeutic Target from the Alloy Therapeutics Mouse
  * Generation Using a Molecular Modeling Platform to Guide Therapeutic Antibody Discovery
  * Optimization of Therapeutic Discovery Strategies for Human Antibody Transgenic Animal Platforms
  * Development of Antibody and PK, and ADA Assays for a Cystine Knot Fusion Protein
  * A Rapid, High-Throughput Recombinant Antibody Expression System for Therapeutic Antibody Discovery and Validation
  * Generation of Agonist and Antagonist Human Monoclonal Antibodies Against an Immune Checkpoint Target from the H2L2 Mouse
  * Generation and Selection of Human Monoclonal Antibodies from the OmniRat
  * Therapeutic Antibody Discovery at Antibody Solutions using the OmniAb Platform
  * Development of human antibodies to human vascular endothelial growth factor -C (VEGF-C) and -D (VEGF-D)
  * Obtaining Antibodies to Difficult Membrane Targets through DNA and Cell Immunization
  * Next-Generation Therapeutic Antibody Discovery from Single B-cells
  * Generation and Selection of Human Monoclonal Antibodies from the H2L2 Mouse
  * Generation of Antibodies to Difficult Membrane Protein Targets
  * Development of Antibodies and ELISAs to measure Free and Total Obiltoxaximab (ETI-204) in the Presence of Anthrax Protective Antigen PA63
  * Discovery of Therapeutic Antibodies to Difficult Membrane Proteins